Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer

Clinical Colorectal Cancer - Tập 6 - Trang 427-432 - 2007
Jordan Berlin1, James Posey2, Simon Tchekmedyian3, Eddie Hu4, David Chan5, Imtiaz Malik6, Liqiang Yang7, Rafael G. Amado7, J. Randolph Hecht8
1Vanderbilt University Medical Center, Nashville, TN, California
2University of Alabama, Birmingham, California
3Pacific Shores Medical Group, Long Beach, California
4Central Hematology/Oncology Medical Group, Monterey Park, California
5Cancer Care Associates Medical Group Inc, Redondo Beach, California
6Loma Linda University Cancer Institute, California
7Amgen, Inc., Thousand Oaks, California
8University of California Los Angeles School of Medicine, California

Tài liệu tham khảo

Jemal, 2007, Cancer statistics, 2007, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43

Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302

Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, 355, 1041, 10.1016/S0140-6736(00)02034-1

Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046

Tournigand, 2004, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study, J Clin Oncol, 22, 229, 10.1200/JCO.2004.05.113

Colucci, 2005, Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale, J Clin Oncol, 23, 4866, 10.1200/JCO.2005.07.113

Giantonio, 2005, High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200, J Clin Oncol, 23, 1s

Hurwitz, 2005, Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer, J Clin Oncol, 23, 3502, 10.1200/JCO.2005.10.017

Lockhart, 2005, The epidermal growth factor receptor as a target for colorectal cancer therapy, Semin Oncol, 32, 52, 10.1053/j.seminoncol.2004.09.036

Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025

Foon, 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody, Int J Radiat Oncol Biol Phys, 58, 984, 10.1016/j.ijrobp.2003.09.098

Malik, 2005, Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (mCRC), J Clin Oncol, 23, 251s

Hecht, 2006, Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr), J Clin Oncol, 24, 157s

Berlin, 2006, Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > 10% epidermal growth factor receptor (EGFr), J Clin Oncol, 24, 158s

Peeters, 2006, A phase 3 multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC), Proc Am Assoc Cancer Res, 47

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Rothenberg, 2001, Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel, J Clin Oncol, 19, 3801, 10.1200/JCO.2001.19.18.3801

2006

Venook, 2006, Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results, J Clin Oncol, 24, 148s

Thông tin
Thông tin xuất bản

Clinical Colorectal Cancer

Tập 6

427-432

Thông tin tác giả